Gan&Lee Pharmaceuticals.603087.SHValuation Analysis

As of Oct 19, 2026, Gan&Lee Pharmaceuticals. (603087.SH) trades at a P/E of 36.30x, P/B of 3.57x, P/S of 9.38x, and a dividend yield of 1.43%.
Longitudinal percentile comparison: P/E sits at the 32nd percentile over the trailing 10Y window (vs. 20th percentile over 3Y); P/B sits at the 68th percentile over the trailing 10Y window (vs. 83rd percentile over 3Y); P/S sits at the 27th percentile over the trailing 10Y window (vs. 40th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 48th percentile within its industry and the 49th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.76%, ranking at the 74th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 35.9 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 1.76% total shareholder yield, 1.43% is paid out as dividends and roughly 0.32% is implied to come from buybacks — both channels are meaningfully in play. Gan&Lee Pharmaceuticals. operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.